The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

Love & Joy Family Clinic announced an expansion of its screening offerings that strengthens the practice's cancer screenin ...

Author:Shweta Raskar, Business Development Specialist, Prophecy Market InsightsIntroductionThe Multi-Cancer Early Detection (MCED) Market is witnessing an unprecedented surge as diagnostic ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with 95% accuracy ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...